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Abstract
Opisthorchiasis, caused by the liver fluke Opisthorchis viverrini, a food-borne
trematode, is an important public health problem; however, only a single drug,
praziquantel is available. We investigated tribendimidine–praziquantel combi-
nations against O. viverrini in vitro and in vivo. The IC50 values of 0.16mg/ml and
0.05mg/ml were determined for praziquantel and tribendimidine, respectively,
against adult O. viverrini in vitro. When O. viverrini was exposed to both drugs
simultaneously (using a drug ratio based on the IC50 (1:3.2)) a synergistic effect
was calculated (combination index (CI) at the IC50 ¼ 0.7). A similar result was
observed when drug addition in vitro was spaced by the respective half-lives of
the drugs (a CI of 0.78 at the IC50 for tribendimidine followed by praziquantel
and a CI of 0.47 at the IC50 for praziquantel followed by tribendimidine). In vivo
median-effect dose (ED50) values of 191 mg/kg and 147 mg/kg were calculated
for praziquantel and tribendimidine, respectively. Low to moderate worm
burden reductions (38–62%) were observed in O. viverrini infected hamsters
when both drugs were administered simultaneously or on subsequent days,
pointing to antagonistic effects in vivo. Further studies are necessary to
understand the striking differences between the in vitro and in vivo observations
using combinations of praziquantel and tribendimidine on O. viverrini.
Introduction
Opisthorchiasis, caused by the liver fluke Opisthorchis
viverrini, a food-borne trematode, is an important public
health problem, with 8 million people being infected in
Cambodia, Lao People’s Democratic Republic (Lao PDR),
Thailand and Viet Nam (Keiser & Utzinger, 2005; Fu¨rst
et al., 2012a; Sithithaworn et al., 2012). The infection is
associated with hepatomegaly, cholangitis, periductal
fibrosis, cholecystitis and, most importantly, cholangio-
carcinoma (Sripa & Pairojkul, 2008; Keiser & Utzinger,
2009; Sripa et al., 2010).
Since treatment and control of this neglected tropical
disease is solely based on praziquantel and drug
resistance remains a threat, we have in the past years
evaluated the opisthorchicidal properties of different
marketed drugs, including the antimalarial agents
artemether, artesunate and mefloquine, and the Chinese
anthelminthic tribendimidine in vitro and in vivo (Keiser
& Utzinger, 2010) and in clinical testing (Soukhathamma-
vong et al., 2011). Promisingly, in a Phase 2 exploratory
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trial in Lao PDR, the highest cure and egg reduction rates
of 70.4 and 99.4%, respectively, were achieved when a
single oral dose of 200 mg (below the age of 14 years)
or 400 mg (above the age of 14 years) tribendimidine
was administered to school-aged children. Artesunate,
mefloquine and artesunate–mefloquine showed only
low activities, while cure and egg reduction rates of
56 and 98.5% were documented for a double dose of
praziquantel (Soukhathammavong et al., 2011).
While combination chemotherapy treatment is com-
monly used in different therapeutic fields, including
the treatment of malaria, cancer and tuberculosis
(Keiser & Utzinger, 2010), to our knowledge the effect
of combination chemotherapy against infections with
O. viverrini has not been studied to date. The most
compelling rationale for combination chemotherapy is an
increased efficacy at lower doses, a decreased toxicity and
a delay of drug resistance.
The aim of the present study was to investi-
gate tribendimidine–praziquantel combinations against
O. viverrini in vitro and in vivo. Note that synergistic effects
were recently observed when this drug combination was
used to treat infections with Clonorchis sinensis, a closely
related liver fluke, in the rat model (Keiser et al., 2009).
Materials and methods
Maintenance and experimental infection of hamsters
In vivo studies were licensed by the local government
(permit no. 2070) and followed Swiss national regulations
and the ARRIVE recommendations (Kilkenny et al., 2010).
Syrian Gold hamsters (male, 3 weeks old) were purchased
from Charles River (Sulzfeld, Germany). Hamsters had
free access to water and rodent diet and were kept in
groups of four in environmentally controlled conditions
(temperature:,258C; humidity:,70%; 12 h light and 12 h
dark cycle). Hamsters were acclimatized for several days
before oral infection with 45 O. viverrini metacercariae,
obtained from the digestion of local fish in Khon Kaen
province, Thailand (Keiser et al., 2006).
Drugs
Praziquantel was purchased from Sigma (Buchs,
Switzerland) and tribendimidine was provided by
Xinhua Pharmaceuticals (Zibo, China). Drugs were
dissolved in 100% dimethyl sulphoxide (DMSO) (Fluka,
Buchs, Switzerland) and prepared as suspensions in 7%
(v/v) Tween 80 and 3% (v/v) ethanol for the in vitro and
in vivo studies, respectively.
In vitro studies
Opisthorchis viverrini worms obtained from untreated
animals were incubated in 2 ml RPMI 1640 culture
medium (supplemented with 100 U/ml penicillin and
100mg/ml streptomycin (Invitrogen, Carlsbad, USA))
and exposed to concentrations of 0.001, 0.01, 0.1 and
1mg/ml tribendimidine or praziquantel. Three worms
were used per concentration. Based on the calculated IC50
values at the 24-h examination time point (0.16mg/ml
for praziquantel and 0.05mg/ml for tribendimidine)
drugs were combined at a fixed dose ratio 1:3.2 and
twofold dilutions carried up and down (0.1 and
0.32mg/ml; 0.05 and 0.16mg/ml; 0.025 and 0.08mg/ml;
0.0125 and 0.04mg/ml of tribendimidine and praziquan-
tel, respectively). In addition, in a second experiment
drug addition was spaced by the respective half-lives of
the drugs (1 h for praziquantel and 4 h for tribendimidine)
(Yuan et al., 2010; Botros et al., 2011). In more detail,
O. viverrini were incubated with (1) praziquantel
(0.16, 0.08 and 0.04mg/ml) followed by tribendimidine
(0.05, 0.025 and 0.0125mg/ml) 1 h post-incubation; and (2)
tribendimidine (0.05, 0.025 and 0.0125mg/ml) followed
by praziquantel (0.16, 0.08 and 0.04mg/ml) 4 h post-
exposure. The effect of each drug concentration (mono-
therapy and combination chemotherapy) was assessed
in duplicate and repeated once. Opisthorchis viverrini
incubated in medium containing the highest solvent
concentration used (1% DMSO) served as controls in
all experiments. Worms were incubated at 378C and 5%
carbon dioxide (CO2) for 24 h, and their viabilities
recorded using a viability scale (4 ¼ very active (similar
movements as control flukes); 3 ¼ active (reduced
motility when compared to control; however, entire
body still moving); 2 ¼ reduced viability (only move-
ments of the sucker visible); 1 ¼ death of worms
(non-motile, elongated shape)) under the microscope
(8- to 40-fold magnification; Carl Zeiss AG, Germany).
The average of motility scores for one drug was calculated
for each concentration and normalized into a percent-
age, relative to the control. IC50 values, defined as
the concentration of a drug required to decrease the
mean worm’s motility to 50% at the 24-h time point,
were expressed based on the median effect principle,
using CompuSyn (version 1.0 ; Combosyn, Paramus, New
Jersey, USA). We used the Chou–Talalay method to
document whether tribendimidine–praziquantel combi-
nations behave additively, antagonistically or synergisti-
cally (Chou, 2010). The CompuSyn software package was
used to calculate median-effect dose (ED50) values, the
combination index (CI) and dose reduction index (DRI)
values, and to draw the dose–response curve and
isobologram plots.
In vivo studies
For the monotherapy in vivo experiments 4 weeks post-
infection, four hamsters each were treated with single oral
doses of 100 and 200 mg/kg praziquantel. Tribendimi-
dine was administered to four hamsters at a dose of
400 mg/kg. For the calculation of the ED50 values a worm
burden reduction obtained with a dose of tribendimidine
(200 mg/kg) in a recent study was included (Keiser et al.,
2007). To determine the combination dose–effect, four
hamsters each were treated (five weeks post-infection)
simultaneously with combinations based on their ED50
values (191 mg/kg for praziquantel plus 147 mg/kg
tribendimidine, and 382 mg/kg praziquantel plus
294 mg/kg tribendimidine). To evaluate whether the
administration schedule has an influence on the activity,
one group of hamsters was treated with 147 mg/kg
tribendimidine followed by 191 mg/kg praziquantel on
the next day. Four untreated hamsters served as controls.
Hamsters were killed by the CO2 method and dissected
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one week post-treatment. All O. viverrini were removed
from the liver, gall bladder and bile ducts and counted.
A difference in the median of the worm burdens in
the control and treatment groups was considered to be
significant at a significance level of 5% using the Kruskal–
Wallis (KW) test (version 2.4.5 StatsDirect (Altrincham,
Cheshire, UK)).
Results
In vitro studies
We first studied the effect of both drugs separately
in vitro. The drug effect was assessed 24 h post-incubation.
IC50 and IC95 values of 0.16mg/ml and 0.99mg/ml, res-
pectively, were determined for praziquantel in vitro.
At a dose of 0.05mg/ml tribendimidine reduced the
viability of O. viverrini by 50% (IC50). The corresponding
IC95 value was 1.22mg/ml. The dose–response curves
of praziquantel and tribendimidine are presented in fig. 1.
For the combination chemotherapy experiments,
O. viverrini were incubated simultaneously in the pre-
sence of both tribendimidine and praziquantel at a ratio
based on their IC50 values (1:3.2). The dose–effect curve of
this combination at the 24-h examination point is shown
in fig. 1. A synergistic effect was calculated for this
combination against O. viverrini in vitro (CI ¼ 0.7 at the
IC50 (synergism) and 0.19 at the IC95 (strong synergism)).
An isobologram for this combination is presented in fig. 2.
The two highest concentrations tested (0.1mg/ml triben-
dimidine and 0.32mg/ml praziquantel and 0.05mg/ml
tribendimidine and 0.16mg/ml praziquantel) resulted in
death of all worms 24 h post-incubation. A 50% viability
reduction was achieved with 0.018mg/ml tribendimidine
plus 0.059mg/ml praziquantel (corresponding to DRI
values of 2.9 and 2.8 for tribendimidine and praziquantel,
respectively). In the next step, in two sets of experiments
O. viverrini was exposed to the drugs spaced by their
respective half-lives. All O. viverrini incubated with
0.16mg/ml praziquantel followed by tribendimidine
(0.05mg/ml) after 1 h were dead after 24 h. When half
of these doses were used, a strongly reduced viability
(viability score ¼ 1.75) was observed at the 24-h exami-
nation time point. At the lowest concentrations tested
(0.04mg/ml praziquantel followed by 0.0125mg/ml
tribendimidine) no effect was observed 24 h post-
incubation. For this spaced co-administration (first
praziquantel followed by tribendimidine) a CI of 0.78 at
the IC50 (synergism) was determined. A similar picture
was observed when the flukes were first exposed to
tribendimidine followed by praziquantel 4 h later. At
the highest concentrations (0.05mg/ml tribendimidine
and 0.16mg/ml praziquantel) all worms were dead.
At the medium concentrations, viability of worms was
highly affected. Finally, at the lowest concentrations
(tribendimidine (0.0125mg/ml) followed by praziquantel
(0.04mg/ml)) worms were still alive, although they were
slightly less active than the control worms. For
this spaced tribendimidine–praziquantel combination
a CI of 0.47 was calculated at the IC50, hence the
combination also shows strong synergistic effects.
In vivo studies
Given the promising in vitro results, which document
synergistic properties of a tribendimidine–praziquantel
combination regardless of the treatment schedule used,
in vivo studies were launched. In a first step, monotherapy
studies were carried out. Worm burden reductions
of 0 and 65.7% (P ¼ 0.03) were achieved by treating
O. viverrini-infected hamsters with 100 and 200 mg/kg
praziquantel (table 1). An ED50 of 191 mg/kg was
determined for praziquantel. For the ED50 calculation
of tribendimidine we included a result obtained from a
previous experiment. At 200 mg/kg tribendimidine a
worm burden reduction of 61.4% was recorded (Keiser
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Fig. 1. Dose–response curves of tribendimidine and praziquantel
and combined tribendimidine–praziquantel (IC50:IC50) against
adult O. viverrini in vitro. Circles (solid line) represent
tribendimidine, squares (broken line) praziquantel and triangles
(broken line) the tribendimidine–praziquantel combination.
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et al., 2007). In the present work, tribendimidine given
at 400 mg/kg to O. viverrini-infected hamsters resulted
in a significant worm burden reduction of 82% (P ¼ 0.03).
Of four hamsters investigated per group, one was cured
following tribendimidine at 400 mg/kg. We calculated
an ED50 of 147 mg/kg for tribendimidine.
Next, combination chemotherapy studies were con-
ducted in vivo. A constant ratio design based on the
ED50 values of both drugs (1:1.3) was used to analyse
whether a praziquantel–tribendimidine combination
reveals additive, antagonistic or synergistic effects in
hamsters. When both drugs were administered simul-
taneously at a dose of 191 mg/kg praziquantel and
147 mg/kg tribendimidine a moderate worm burden
reduction of 62.5% (P ¼ 0.03) was observed. None of
the hamsters was cured. Doubling both doses even
lowered the efficacy and low, not significant worm burden
reductions of 38% were documented. The ED50 dose of the
combination was calculated as 493 mg/kg (279 mg/kg
praziquantel and 214 mg/kg tribendimidine). A CI of
2.9 was determined at the median dose effect level,
revealingantagonisticeffectsof this combination invivo. We
therefore tested whether the timing of drug co-adminis-
tration might have an influence on the opisthorchicidal
activity of the tribendimidine–praziquantel combination.
However, when the drugs were administered on sub-
sequent days, first tribendimidine followed by 191 mg/kg
praziquantel after 24 h, a low worm burden reduction of
39.7% (P ¼ 0.28) was documented.
Discussion
An estimated 8 million people are infected with
O. viverrini, accounting for 74,000 disability-adjusted life
years (DALYs) (Fu¨rst et al., 2012a). Heavily infected
individuals often present with a series of symptoms,
including severe consequences such as obstructive
jaundice, biliary colic and cholangiocarcinoma (Fu¨rst
et al., 2012b). Yet only a single drug is available for
treatment of this neglected tropical disease. To our
knowledge, tribendimidine is the only alternative drug
development candidate for the treatment of infections
with O. viverrini.
In the present work we studied the effect
of praziquantel–tribendimidine combinations against
O. viverrini in vitro and in vivo. While synergistic to
highly synergistic effects were documented when
O. viverrini were exposed to tribendimidine–praziquantel
in vitro, disappointingly only low, antagonistic activities
were observed in vivo using a ratio based on the ED50
values of the drugs. Interestingly, these contradictory
effects were not only observed when the drugs were
administered simultaneously but also following a spaced
drug administration. The striking differences between the
in vitro and in vivo observations cannot be explained at the
moment. It is worth emphasizing that synergistic effects
were observed against the closely related liver fluke,
C. sinensis, although in a rat and not in a hamster model
(Keiser et al., 2009). Pharmacokinetic or pharmaco-
dynamic drug interactions are likely to occur, which
should be further studied. In addition, studies have
shown that whether combinations of anticancer drugs
interact synergistically or antagonistically can depend on
the ratio of the combined agents (Harasym et al., 2010).
Hence, it might be worthwhile to assess tribendimidine–
praziquantel in vivo using other ratios besides a ratio
based on the ED50 values used in the present study.
In conclusion, a tribendimidine–praziquantel combi-
nation does not offer therapeutic benefit over tribendi-
midine or praziquantel monotherapy in the hamster
model. Nonetheless, the opisthorchicidal properties
of tribendimidine should be further studied in great
detail as presently there is no other trematocidal drug
candidate on the horizon. Dose-finding and pharmaco-
kinetic studies with tribendimidine in O. viverrini-
infected patients have been launched in Lao PDR.
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